» Articles » PMID: 22931300

Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for >200 Compounds

Overview
Specialty Toxicology
Date 2012 Aug 31
PMID 22931300
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Drug-induced liver injury is the most common cause of market withdrawal of pharmaceuticals, and thus, there is considerable need for better prediction models for DILI early in drug discovery. We present a study involving 223 marketed drugs (51% associated with clinical hepatotoxicity; 49% non-hepatotoxic) to assess the concordance of in vitro bioactivation data with clinical hepatotoxicity and have used these data to develop a decision tree to help reduce late-stage candidate attrition. Data to assess P450 metabolism-dependent inhibition (MDI) for all common drug-metabolizing P450 enzymes were generated for 179 of these compounds, GSH adduct data generated for 190 compounds, covalent binding data obtained for 53 compounds, and clinical dose data obtained for all compounds. Individual data for all 223 compounds are presented here and interrogated to determine what level of an alert to consider termination of a compound. The analysis showed that 76% of drugs with a daily dose of <100 mg were non-hepatotoxic (p < 0.0001). Drugs with a daily dose of ≥100 mg or with GSH adduct formation, marked P450 MDI, or covalent binding ≥200 pmol eq/mg protein tended to be hepatotoxic (∼ 65% in each case). Combining dose with each bioactivation assay increased this association significantly (80-100%, p < 0.0001). These analyses were then used to develop the decision tree and the tree tested using 196 of the compounds with sufficient data (49% hepatotoxic; 51% non-hepatotoxic). The results of these outcome analyses demonstrated the utility of the tree in selectively terminating hepatotoxic compounds early; 45% of the hepatotoxic compounds evaluated using the tree were recommended for termination before candidate selection, whereas only 10% of the non-hepatotoxic compounds were recommended for termination. An independent set of 10 GSK compounds with known clinical hepatotoxicity status were also assessed using the tree, with similar results.

Citing Articles

Prediction of cytochrome P450-mediated bioactivation using machine learning models and in vitro validation.

Hu X, Hou Y, Teng X, Liu Y, Li Y, Li W Arch Toxicol. 2024; 98(5):1457-1467.

PMID: 38492097 DOI: 10.1007/s00204-024-03701-w.


Evaluation of the Drug-Induced Liver Injury Potential of Saxagliptin through Reactive Metabolite Identification in Rats.

Kim K, Jeong Y, Park S, Park E, Jeon J, Song I Pharmaceutics. 2024; 16(1).

PMID: 38258116 PMC: 10819019. DOI: 10.3390/pharmaceutics16010106.


3D human tissue models and microphysiological systems for HIV and related comorbidities.

Trends Biotechnol. 2023; 42(5):526-543.

PMID: 38071144 PMC: 11065605. DOI: 10.1016/j.tibtech.2023.10.008.


A blinded in vitro analysis of the intrinsic immunogenicity of hepatotoxic drugs: implications for preclinical risk assessment.

Ogese M, Lister A, Farrell L, Gardner J, Kafu L, Ali S Toxicol Sci. 2023; 197(1):38-52.

PMID: 37788119 PMC: 10734620. DOI: 10.1093/toxsci/kfad101.


Elucidation of the relationship between evodiamine-induced liver injury and CYP3A4-mediated metabolic activation by UPLC-MS/MS analysis.

Peng T, Rao J, Zhang T, Wang Y, Li N, Gao Q Anal Bioanal Chem. 2023; 415(23):5619-5635.

PMID: 37433953 DOI: 10.1007/s00216-023-04831-3.